TIDMSBTX
RNS Number : 3967D
SkinBioTherapeutics PLC
19 February 2020
SkinBioTherapeutics plc
SkinBioTherapeutics signs agreement with Winclove Probiotics to
develop psoriasis food supplement
-- Commencement of new strategic pillar for SkinBioTherapeutics, targeting the gut-skin axis
-- Second deal signed, demonstrating continued focus and delivery on commercial strategy
Manchester, UK - 19 February 2020 - SkinBioTherapeutics plc
(AIM: SBTX - "SkinBioTherapeutics" or the "Company" ), a life
science company focused on skin health, announces that its wholly
owned subsidiary, AxisBiotix Limited, has signed a development
agreement with Winclove Probiotics B.V., ("Winclove") , a
specialist in the research, development and manufacture of
probiotic food formulations and supplements, to help manage the
symptoms associated with the skin condition, psoriasis .
SkinBioTherapeutics and Winclove will design and develop a
probiotic blend of 'good' bacterial strains based on the modifying
properties of specific bacterial species on known psoriasis disease
pathways.
This blend will be developed into a probiotic food supplement
which will be called AxisBiotix(TM). SkinBioTherapeutics will be
responsible for the identification and selection of the bacterial
strains and patient testing; Winclove will be responsible for the
formulation and manufacture of AxisBiotix (TM) . The development
agreement is for a period of three years but can be extended by
mutual agreement. Each party retains ownership of its respective
intellectual property and will be responsible for their own costs
in relation to the development programme.
As a pre-requisite to commercialisation, AxisBiotix(TM) will be
tested in a UK human study for patients suffering from mild to
moderate psoriasis. The study, to be managed by
SkinBioTherapeutics, is expected to start in 2020 and is estimated
to take approximately 12-18 months to complete. On the basis of a
positive read-out, SkinBioTherapeutics will then proceed with
commercialisation and the parties have stated their intention for a
commercial launch within 24 months of the completed development
programme.
Psoriasis is a debilitating skin condition caused by a
malfunction of the immune system whereby skin cells are replaced
more quickly than normal. This causes an accumulation of skin cells
which build up to form raised 'plaques' on the skin, which can also
be flaky, scaly and itchy. There is no cure; mainstay therapies
tend to be steroid-based, which cannot be used long term and have
side effects. Worldwide, approximately 2% of the population is
believed to suffer from the condition and the global psoriasis
market was valued at approximately $30bn in 2018 and is expected to
grow to $47bn in 2022 at a CAGR of 11.5%.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"There is strong scientific evidence pointing to a link between
gut dysfunction, stress-induced alterations to the gut microbiome
and skin inflammation. We believe that in this partnership with
Winclove, which was initiated by our CSO, Prof. Cath O'Neill, we
can create a specific probiotic food supplement that has the
potential to help manage the hard-to-treat symptoms of
psoriasis.
" This agreement with Winclove represents the next phase of
SkinBioTherapeutics' strategy to develop new avenues of
microbiome-based technology, this time focused on the gut-skin
axis. It also represents the second phase of our strategic plan,
following our recent agreement with Croda plc in the active
skincare sector."
Maarten Pekelharing, CEO of Winclove, said:
" We have developed business partnerships across the world and a
key criteria for us is that our partners share our ambition to make
a difference in people's health and want to use their businesses as
a force for good.
"We are proud to begin a collaboration with SkinBioTherapeutics
and feel privileged to work with such a renowned scientist as Prof.
Catherine O'Neill.
"Since 1991 our founding fathers, Bram van Leeuwen and Pieter
Pekelharing, were fascinated by probiotics and believed strongly in
the importance of probiotics and their effect on our microbiome.
This fascination and belief is still the ethos of our family-owned
company today. We are very excited to help SkinBioTherapeutics
develop and bring to market together a new probiotic formulation
for such an innovative scientific area as the gut-skin axis with
the potential to enhance the quality of life for people with
difficult to treat skin conditions like psoriasis."
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart Ashman, CEO 468 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20
Adviser) 7213 0880
Tony Rawlinson / Sandy Jamieson
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20
Andy Thacker / Zoe Alexander 3657 0050
SP Angel Corporate Finance (Joint Broker)
Vadim Alexandre / Abigail Wayne Tel: +44 (0) 20
3470 0470
Instinctif Partners Tel: +44 (0) 20
Melanie Toyne-Sewell / Philip Marriage 7457 2020
/ Nathan Billis SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Dr. Catherine
O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that
the SkinBiotix(R) platform can improve the barrier effect of skin
models, protect from infection and repair wounds. Proof of
principle studies have also shown that the SkinBiotix(R) platform
has beneficial attributes applicable to each of these areas. The
technology achieved positive results in clinical studies in human
volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information, visit:
www.skinbiotherapeutics.com .
About Winclove Probiotics B.V.
Winclove Probiotics has been specializing in researching,
developing and manufacturing probiotic formulations for specific
indications since 1991. It specialises in food supplements, working
with partners to help develop and market its formulations. Winclove
Probiotics is a leader in the field and committed to improve
quality of life for as many people as possible.
Research is the foundation of Winclove Probiotics' probiotic
formulations. It has over 25 years of experience in the field of
research and product development. Over the years it has
successfully combined probiotic strains with unique functionalities
into innovative multispecies formulations. Its formulations are
used in more than 35 countries worldwide
For more information about Winclove Probiotics, please visit
www.wincloveprobiotics.com .
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRVVLFFBLLLBBF
(END) Dow Jones Newswires
February 19, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Skinbiotherapeutics (LSE:SBTX)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Skinbiotherapeutics (LSE:SBTX)
Storico
Da Apr 2023 a Apr 2024
